These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 25967287)

  • 1. Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study.
    Osawa M; Kudoh S; Sakai F; Endo M; Hamaguchi T; Ogino Y; Yoneoka M; Sakaguchi M; Nishimoto H; Gemma A
    Int J Clin Oncol; 2015 Dec; 20(6):1063-71. PubMed ID: 25967287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.
    Yamada T; Moriwaki T; Matsuda K; Yamamoto Y; Sugaya A; Akutsu D; Murashita T; Endo S; Hyodo I
    Onkologie; 2013; 36(4):209-12. PubMed ID: 23548971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients.
    Boku N; Sugihara K; Kitagawa Y; Hatake K; Gemma A; Yamazaki N; Muro K; Hamaguchi T; Yoshino T; Yana I; Ueno H; Ohtsu A
    Jpn J Clin Oncol; 2014 Mar; 44(3):214-23. PubMed ID: 24526771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
    Endo M; Johkoh T; Kimura K; Yamamoto N
    Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
    Chen Y; Noma S; Taguchi Y; Takahashi M; Tsurutani J; Mori S; Sakaguchi S; Asou H; Tomii K
    Breast Cancer; 2021 May; 28(3):710-719. PubMed ID: 33453015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports.
    Yoshii N; Suzuki T; Nagashima M; Kon A; Kakihata K; Gemma A
    Anticancer Drugs; 2011 Jul; 22(6):563-8. PubMed ID: 21562406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib--a cohort study.
    Johkoh T; Sakai F; Kusumoto M; Arakawa H; Harada R; Ueda M; Kudoh S; Fukuoka M
    Clin Lung Cancer; 2014 Nov; 15(6):448-54. PubMed ID: 25043209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial Lung Disease Onset and Its Risk Factors in Japanese Patients With ALK-Positive NSCLC After Treatment With Crizotinib.
    Gemma A; Kusumoto M; Kurihara Y; Masuda N; Banno S; Endo Y; Houzawa H; Ueno N; Ohki E; Yoshimura A
    J Thorac Oncol; 2019 Apr; 14(4):672-682. PubMed ID: 30521972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
    Rezkallah KNM; Ahmed A; Patel S; Kozma K
    BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30739089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
    Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer.
    Makris D; Scherpereel A; Copin MC; Colin G; Brun L; Lafitte JJ; Marquette CH
    BMC Cancer; 2007 Aug; 7():150. PubMed ID: 17683587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
    BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer).
    Tomii K; Kato T; Takahashi M; Noma S; Kobashi Y; Enatsu S; Okubo S; Kobayashi N; Kudoh S
    Jpn J Clin Oncol; 2017 Apr; 47(4):350-356. PubMed ID: 28158568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
    Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
    Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum.
    Yakar N; Ergun B; Ugur L; Ates UC; Gezer S; Comert B
    J Oncol Pharm Pract; 2021 Dec; 27(8):2061-2065. PubMed ID: 34000921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.